Timblin, Greg A. http://orcid.org/0000-0001-9351-3646
Tharp, Kevin M.
Ford, Breanna
Winchester, Janet M.
Wang, Jerome
Zhu, Stella
Khan, Rida I.
Louie, Shannon K.
Iavarone, Anthony T.
ten Hoeve, Johanna
Nomura, Daniel K.
Stahl, Andreas
Saijo, Kaoru http://orcid.org/0000-0003-1656-1753
Funding for this research was provided by:
American Diabetes Association (1-19-PDF-058)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (1F32CA236156-01A1)
ICAR-Indian Veterinary Research Institute
Berkeley IVRI funding and Pew Scholar Award.
Article History
Received: 24 July 2020
Accepted: 15 April 2021
First Online: 20 May 2021
Competing interests
: G.A.T. and K.S. are co-inventors on provisional patent application no. 63/091,217 filed by UC Berkeley describing methods of use of hydroxyoestrogen for treatment of inflammatory and metabolic disease. G.A.T. is co-founder of a start-up focused on therapeutic applications of hydroxyoestrogen derivatives. D.K.N. is a shareholder and adviser for Frontier Medicines. The other authors declare no competing interests.